Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Discovery: Overview
Clinical Trials: Overview
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Robert M Califf1, Stephen Ostroff2
1Robert M. Califf is Deputy Commissioner for Medical Products and Tobacco at the U.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.Stephen Ostroff is Acting Commissioner at FDA, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA. robert.califf@fda.hhs.gov.
No abstract available in PubMed .